Cancer Genetics will offer biopharma company ApoCell’s ApoStream™ technology for the detection, isolation, and enrichment of rare and circulating tumor cells (CTCs) across a variety of cancers, said the companies said today, through an agreement whose value was not disclosed.

The companies said they will work on clinical trial projects that support the liquid biopsy and CTC profiling needs in multiple trials for both targeted therapeutics and immuno-oncology.

In addition, Cancer Genetics and ApoCell said they will evaluate applications for patient monitoring in lung, colorectal, breast, and renal cancer. The companies have launched joint projects where rare cell capture is coupled with Cancer Genetics’ downstream, disease-specific profiling intended to evaluate therapeutic effectiveness.

ApoCell is a spin-out of University of Texas MD Anderson Cancer Center and licenses key technology used in ApoStream from the Center. ApoCell co-developed ApoStream with the National Cancer Institute (NCI) from 2010 through 2014, with initial commercial delivery in 2013.

According to the companies, ApoStream has been incorporated into over 35 clinical trials, including trials for prostate, lung, breast, colon, pancreatic, and renal cancers. In a recent global Phase III breast cancer trial, ApoStream detected and analyzed CTCs in over 97% of the 649 women who participated. ApoCell has also sought to develop the technology for high-volume capture of CTCs.